Perrigo Confirms First To File Patent Challenge For Generic Version Of ProAir HFA Inhalation Aerosol
Perrigo Company (Nasdaq: PRGO) (NASDAQ: TASE) announced that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for albuterol sulfate HFA inhalation aerosol, the generic version of ProAir® HFA. The ANDA filing involved contributions from both Perrigo and Catalent Pharma Solutions, Inc., who partnered on the development of this project.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.